--- title: "U.S. stock market update: Aveanna Healthcare up 9.08%: Earnings exceeded expectations and guidance raised, institutions target up to $15" type: "News" locale: "en" url: "https://longbridge.com/en/news/295966286.md" description: "Aveanna Healthcare rose 9.08%; Syneos Health rose 2.36%, with a trading volume of USD 608 million; Hims & Hers Health fell 1.76%, with a trading volume of USD 178 million; Cigna rose 1.48%, with a trading volume of USD 118 million; Quest Diagnostics fell 0.46%, with a market value of USD 26 billion" datetime: "2026-08-14T19:08:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295966286.md) - [en](https://longbridge.com/en/news/295966286.md) - [zh-HK](https://longbridge.com/zh-HK/news/295966286.md) generator: "portal-rs" --- # U.S. stock market update: Aveanna Healthcare up 9.08%: Earnings exceeded expectations and guidance raised, institutions target up to $15 **U.S. Stock Market Midday Update** Aveanna Healthcare rose 9.08%. Based on recent key news: 1. On August 13, Aveanna Healthcare announced its second-quarter financial report, with revenue reaching $670.5 million, a year-on-year increase of 13.7%, and a net profit of $40.3 million, exceeding analyst expectations. This performance drove the stock price up. 2. On August 14, Aveanna Healthcare announced an upward revision of its full-year revenue forecast to over $2.68 billion, an increase from previous expectations, demonstrating the company's confidence in future growth and further boosting the stock price. 3. On August 15, Raymond James raised Aveanna Healthcare's target stock price from $13 to $15, reflecting market optimism about the company's future performance, driving the stock price to continue rising. The healthcare industry is performing strongly, with significant capital inflows. **Stocks with High Trading Volume in the Industry** CVS rose 2.36%. Based on recent key news: 1. On August 14, Mubadala Investment Company increased its holdings in CVS to 163,902 shares, showing confidence in the company's future, which drove the stock price up. 2. On August 13, Bernstein and JP Morgan maintained a buy rating for CVS, with target prices of $106 and $118 respectively, as analysts hold an optimistic view on the company's prospects, further supporting the stock price increase. 3. On August 12, CVS Health issued a press release through PR Newswire, emphasizing the company's leadership and innovation in the healthcare sector, enhancing market confidence. The healthcare industry has performed strongly recently, with significant capital inflows. HIMS fell 1.76%, with a trading volume of $178 million. Based on recent key news: 1. On August 12, Hims & Hers Health's stock price fell due to its shift towards the peptide market. Despite sales exceeding expectations, the market raised doubts about its potential in the peptide market, leading to a decline in stock price. Source: Benzinga 2. On August 13, the FTC filed a lawsuit against Hims & Hers Health, accusing it of sharing sensitive health information of consumers on advertising platforms, increasing legal risks. Source: MarketWatch 3. On August 12, analysts maintained a neutral rating on Hims & Hers Health, raising the target price to $42, showing market confidence in its long-term growth potential. Source: Gelonghui The digital health industry faces compliance risks and cost pressures. Cigna rose 1.48%. Based on recent key news: 1. On August 14, Cigna Group announced a cash dividend of 0.22 riyals per unit for the third quarter of 2026. This news enhanced investor confidence, driving the stock price up 2. On August 14, Mubadala Investment Co PJSC increased its holdings in Cigna Group to 45,512 shares. This move shows institutional investors' optimism towards Cigna, further boosting its stock price. 3. On August 15, PCMA CEO David Marin stated that the TrumpRx platform will help consumers better compare drug prices, increasing market attention on Cigna. The overall industry performed well, with noticeable capital inflows. **Stocks ranked among the top in industry market capitalization** Quest Diagnostics fell 0.46%. Based on recent key news: 1. On August 14, Quest Diagnostics announced a quarterly dividend of 1.5 reais per unit for Q4 2026, causing fluctuations in its stock price. The dividend payment date is set for October 27, and the stock price experienced volatility before the ex-dividend date. 2. On August 13, Quest Diagnostics announced a quarterly cash dividend of $0.86 per share, with a payment date of October 21, leading to fluctuations in its stock price following the dividend announcement. 3. On August 14, detailed analysis by analysts on Quest Diagnostics indicated that it may be undervalued or overvalued, leading to market discrepancies in its valuation and causing stock price fluctuations. The overall industry remained stable, with limited impact from macroeconomic data ### Related Stocks - [AVAH.US](https://longbridge.com/en/quote/AVAH.US.md) - [CVS.US](https://longbridge.com/en/quote/CVS.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [CI.US](https://longbridge.com/en/quote/CI.US.md) - [DGX.US](https://longbridge.com/en/quote/DGX.US.md) ## Related News & Research - [Major Insider Move at Aveanna Healthcare Holdings Shakes Up Investor Sentiment](https://longbridge.com/en/news/296871963.md) - [Aveanna Healthcare Chief Administrative Officer Edwin C. Reisz sells 50,000 shares for $575,000](https://longbridge.com/en/news/296826009.md) - [Aveanna management presents at Jefferies Healthcare Services and Technology Conference](https://longbridge.com/en/news/296901807.md) - [Aveanna Healthcare sells 15M shares in $11.75 secondary offering; company received no proceeds](https://longbridge.com/en/news/296826588.md) - [AVAH: Q2 2026 delivered double-digit revenue and net income growth, prompting raised full-year guidance](https://longbridge.com/en/news/295788801.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**